Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG) is a pioneering American corporation headquartered in Sunnyvale, California. The company specializes in the development, manufacturing, and marketing of advanced robotic products that enhance clinical outcomes through minimally invasive surgical techniques. The cornerstone of Intuitive Surgical's innovation is the da Vinci Surgical System, a state-of-the-art robotic platform designed to facilitate complex surgeries with precision and control.
Intuitive Surgical's mission is to transform the surgical experience by providing surgeons with innovative tools that enable better patient outcomes. The da Vinci Surgical System offers a highly magnified, three-dimensional view and robotic assistance, helping surgeons perform precise dissections and reconstructions deep within the body. The system includes several models, including the multiport da Vinci X and Xi and the single-port da Vinci SP, giving hospitals and surgeons versatile options tailored to their needs.
The company has successfully installed over 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 of these installations in the United States alone. The growing presence of these systems in emerging markets underscores the global demand for cutting-edge surgical technology.
In recent news, Intuitive Surgical announced the FDA clearance of its latest generation system, the da Vinci 5, which builds on over a decade of research and offers more than 150 enhancements. This new system aims to improve patient outcomes further, enhance the surgical experience, and reduce overall healthcare costs. Initial deployment of the da Vinci 5 will be limited to select U.S. hospitals with mature robotic surgery programs, before a broader commercial launch.
Intuitive's financial performance remains robust, as highlighted in its recent quarterly reports. The company continues to experience growth in revenue and market penetration, driven by the increasing adoption of robotic-assisted surgery. Its strategic partnerships and collaborations further solidify its market leadership and commitment to innovation.
Intuitive Surgical also emphasizes continuous learning and support for surgical teams, offering comprehensive training programs and educational resources to ensure optimal use of its technologies. The company's dedication to advancing healthcare is reflected in its robust research and development initiatives, aimed at expanding the capabilities and applications of robotic-assisted surgery.
For more detailed financial and operational updates, please visit Intuitive Surgical's official website at www.intuitive.com.
Intuitive (Nasdaq: ISRG) reported strong Q1 2023 financial results, with revenue of $1.70 billion, a 14% increase compared to Q1 2022. The growth was driven by a 26% rise in da Vinci procedures despite ongoing COVID-19 disruptions in China. The company placed 312 da Vinci Surgical Systems, maintaining a steady growth of its installed base to 7,779 systems, a 12% increase year-over-year. Non-GAAP net income was $437 million, or $1.23 per diluted share, up from $413 million, or $1.13 per diluted share in Q1 2022. However, GAAP net income decreased slightly to $355 million from $366 million year-over-year. The company ended the quarter with $6.58 billion in cash and cash equivalents, reflecting share repurchases of $350 million.
Intuitive (Nasdaq: ISRG) announced fourth-quarter 2022 results, reporting revenue of $1.66 billion, a 7% increase from Q4 2021. Worldwide da Vinci procedures rose approximately 18%, but were affected by COVID-19 surges in China. The company placed 369 da Vinci Surgical Systems, down 4% from the previous year, while the installed base grew to 7,544 systems, a 12% increase.
GAAP net income was $325 million or $0.91 per diluted share, down from $381 million or $1.04 per share in Q4 2021. The company repurchased $1 billion in stock during the quarter, ending with $6.74 billion in cash and equivalents.
Intuitive (Nasdaq: ISRG) announced preliminary financial results for Q4 and full year 2022. Fourth quarter revenue reached approximately $1.66 billion, up 7% year-over-year, while full-year revenue was about $6.22 billion, a 9% increase. The company experienced an 18% growth in worldwide da Vinci procedures for Q4 2022, despite disruptions from COVID-19 in China. However, the placement of da Vinci Surgical Systems declined by 4% in Q4 and 6% for the year. The company anticipates a 12% to 16% increase in procedures for 2023.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
What is Intuitive Surgical Inc.?
What is the da Vinci Surgical System?
How many da Vinci systems are installed globally?
What recent achievements has Intuitive Surgical announced?
Are there different models of the da Vinci system?
What is the company's focus regarding patient care?
Where is Intuitive Surgical headquartered?
Does Intuitive Surgical offer training for its systems?
How can I get more information about Intuitive Surgical's financial performance?
What is the significance of the da Vinci 5 system?
